OncoMatch/Clinical Trials/NCT06182774
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma
Is NCT06182774 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Daratumumab and Lenalidomide for multiple myeloma.
Treatment: Daratumumab · Lenalidomide · Dexamethasone · Isatuximab — Currently, daratumumab or isatuximab are given continuously (non-stop), along side lenalidomide, and dexamethasone as part of multiple myeloma treatment. are given continuously (non-stop). Recent observations suggest that stopping daratumumab or isatuximb after about a year and a half of treatment may work just as well as giving them continuously with lenalidomide and dexamethasone. Sometimes, bortezomib is also given. This study is being done to answer the question: is less daratumumab or isatuximab treatment as good as more?
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: daratumumab-lenalidomide-dexamethasone or isatuximab-lenalidomide-dexamethasone (daratumumab, lenalidomide, dexamethasone, isatuximab) — newly diagnosed
Completed 18-20 cycles of daratumumab-lenalidomide-dexamethasone or isatuximab-lenalidomide-dexamethasone.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06182774 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received daratumumab-lenalidomide-dexamethasone or isatuximab-lenalidomide-dexamethasone.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages